From April 16 to 19, Urals Healthcare 2019, the specialized International Exhibition and Forum, was held at the Yekaterinburg Expo Centre, where a stand of Medsintez was presented too. The forum exhibition of medical equipment, tools, supplies, pharmaceuticals as well as medical and spa services was held for the first time ever.
The «Medsintez» plant presented samples of «Rosinsulin®», a proprietary substance of genetic engineering and analog human insulin; samples of finished dosage forms of insulin in bottles, cartridges and pre-filled syringe pens; Triazavirin®, an innovative antiviral drug effective against more than 15 viral infections, as well as samples of infusion solutions of 50 to 5000 ml.
Medsintez's pharmaceutical direction is driven by implementation of some projects dealing with arranging the manufacturing of medicines and active pharmaceutical substances of genetic-engineered and analoginsulins for subsequent use in our own production of finished dosage forms. At the moment, the company has developed a technology for obtaining the RosinsulinAspart and RosinsulinGlargin substances. Finished dosage forms based on Aspart, Medsintez's proprietary insulin substance, are planned to enter the market by 2019, while Glargin insulin - by 2021.
In addition, Medsintez's high-tech equipment allows us to participate in other import-substitution projects too. The contact manufacturing was presented at the exhibition by Primapur®, a recombinant follicle-stimulating human hormone, which comes in pre-filled disposable syringe pens developed at the Medsintez plant. The drug has undergone clinical trials, the results of which were submitted to the Ministry of Health of the Russian Federation. The Medsintez plant is ready to launch, on its premises, the production of a new domestic follitropin alpha, which has gone through all development stages in Russia, from deriving producer cells and obtaining an active hormone to the production of substance and a finished dosage form in a unique syringe pen.
On the premises of the Medsintez plant, which is a modern pharmaceutical enterprise, the production of finished solid dosage forms of the original antiviral drug Triazavirin, which is effective against a wide range of viruses, has been organized. Currently, a number of research projects are underway, whereof purpose is to create new azoloazine-class molecules with a powerful antiviral effect against a variety of viral infections, including hemorrhagic fevers, tick-borne encephalitis and others.
The business program was an important part of the exhibition. On the first day, a meeting of the Expert Council of the Health Protection Committee of the State Duma of the Federal Assembly of the Russian Federation was held, which brought together healthcare representatives of 10 regions of the Ural and Volga Federal Districts. The meeting's subject was discussing amendments to the Law No. 61 “On the Medicine Circulation (regarding the drug registration).” The meeting participants asked questions and expressed their proposals on improving and boosting the drug registration process. On behalf of the Medsintez plant, a report was delivered by Irina Makarova, head of Medsintez's registration department. At the end of the discussion, Alexander Petrov, Russian State Duma Deputy and Chairman of the Subcommittee on medical-purpose drug circulation, taking into account all the claims and wishes of the speakers, assured that this urgent issue would be resolved.
“This exhibition should demonstrate the healthcare progress not only in the Urals but also in other nearby regions. To help us see what our new hospitals, clinics and equipment will look like. And most importantly, to give the residents a different look at healthcare,” said Alexander Petrov, deputy of the State Duma of the Federal Assembly of the Russian Federation.